

Recent emerging gut microbiome management modalities in acute diarrhea in children: (a comparative study review of different probiotic strains). An update. !

Yara K. G. Osman¹, Wafaa S. M. Hegab³, Said M. M. El Deib^{2*}, Gehan I. Mohamed⁵, Malak A. Alia⁴, Amr I. M. Hawal^{6*},

¹Pediatrics & Neonatology, Amina Hospital Ajman, Anglo-Arabian Health Care Group, Dubai, Uae,

²Pediatrics Dep., Royal NMC Hospital, Abu Dhabi, Uae,

³Endocrinology Dep., The National Egyptian Institute of Diabetes & Endocrine Diseases, Egypt, ⁴Pediatrics Dep., Prime MC Ajman, Prime Health Care Group, Dubai, Uae,

⁵Family Medicine, PHC, Saudi MOH, Riyadh, Saudi Arabia.

⁶Amina Hospital Ajman (P.O. Box 5625, Ajman – UAE

***Corresponding Authors:** AMR I.M. Hawal, Amina Hospital Ajman (P.O. Box 5625, Ajman – UAE and Said M, M, El Deib, Royal NMC health care group, Abu Dhabi – UAE.

Received Date: August 23, 2020; **Accepted Date:** August 27, 2020; **Published Date:** September 11, 2020

Citation: Amr I. M. Hawal, Wafaa S. M. Hegab, Said M. M. El Deib, Gehan I. Mohamed, Malak A. Alia, Yara K. G. Osman, (2020) Recent emerging gut microbiome management modalities in acute diarrhea in children: (a comparative study review of different probiotic strains). An update! J Clinical Case Reports and Studies, 1(6): Doi: [10.31579/2690-8808/023](https://doi.org/10.31579/2690-8808/023)

Copyright: © 2020. AMR I.M. Hawal. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Aims & Objectives: Acute Diarrhea (AD) is a highly prevalent condition that causes significant morbidity and mortality worldwide. Conventional therapies include oral Rehydration Solutions (ORS), Antibiotics and Zinc Products. Emerging data suggest that Probiotics use in the treatment & control of AD cases in children may help supplement current therapies for further control.

Methods: Herein, we review the evidence of several Probiotics modalities for AD treatment. We describe the Clinical Impact & prevalence of Acute Diarrhea in children and its complications, provide an overview of current treatments, and finally, discuss recent emergent Gut approaches to AD management. Specifically, we will describe - in a Comparative study - on the utility of different kinds of Probiotics known & used and common natural products in the treatment of Acute cases of AD and focus on recent, high-quality studies. Adverse effects and potential interactions of each therapy will be highlighted where applicable.

Keywords: Probiotic strains; A. Diarrhea; Intestinal colonization; GUT Microbiome, Dehydration; LrGG

Introduction

Acute Diarrheal Diseases considered as the most common leading causes of children mortality all over the globe. Today, only 39 per cent of children with Diarrhea in developing countries receive the recommended treatment, and limited trend data suggest that there has been little progress since 2000, more than 386000 children dies in India only due to A. Diarrhea every year.

An international commitment to tackle childhood Diarrhea in the 1970s and 1980s resulted in a major reduction in child deaths. This came about largely through the scaling up of oral rehydration therapy, coupled with programs to educate caregivers on its appropriate use. But these efforts lost momentum as the world turned its attention to other global emergencies.

Our review aims to search & updates the Evidence-Based Review Articles that study the use of specific probiotic strains, namely *Lactobacillus rhamnosus GG* (LGG) and *Saccharomyces boulardii*, for the management

of children with acute gastroenteritis (AGE) as an adjunct to rehydration therapy.

This Literature Review also aim to show us the role of different probiotics in the treatment of acute diarrhea in children.

“Probiotics may be an effective adjunct to the management of diarrhea”.

L. rhamnosus GG (LGG) significantly reduced duration of diarrhea, daily stool outputs, improved stool consistency and reduced no. of hospitalization and fever in children

Compared to other probiotics (*B. clausii* and *S. boulardii*) & ORS group as we will discuss now.

The guidelines recommend the use of the specific probiotic strains, namely *Lactobacillus rhamnosus GG* (LGG) and *Saccharomyces boulardii*, for the management of children with acute gastroenteritis (AGE) as an adjunct to rehydration therapy.

Discussion:

Trusted evidence.
Informed decisions.
Better health.

[Cochrane.org](#)
[Login/Register](#)

[Cochrane Reviews](#)
[Trials](#)
[More Resources](#)

Cochrane Database of Systematic Reviews

Probiotics for treating acute infectious diarrhoea

[Review](#)
[Intervention](#)

Stephen J Allen, Elizabeth G Martinez, Germana V Gregorio, Leonila F Dans

First published: 10 November 2010

Editorial Group: [Cochrane Infectious Diseases Group](#)

DOI: 10.1002/14651858.CD003048.pub3 [View/save citation](#)

Cited by (CrossRef): 71 articles [Check for updates](#) | [Citation tools](#)



PDF



Info



References



Figures



The Efficacy of any probiotic is strain-dependent;

* Lactobacillus acidophilus strain is effective in IBS but not in AAD.

** Bifidobacterium bifidum reported that one strain (CIDCA5310) inhibited enterocyte invasion by Salmonella arizonae, whereas the other (CIDCA 537) had no effect.

*** Lactobacillus rhamnosus GG (ATCC) help in treatment of Acute diarrhea, Persistent diarrhea, Rotavirus diarrhea, Gastroenteritis, AAD (Antibiotic Associated Diarrhea) Prevention & Treatment, Traveller's diarrhea, Nosocomial diarrhea, Irritable Bowel Syndrome (IBS), Abdominal pain, Crying etc. , Ulcerative colitis, Necrotizing Enterocolitis (NEC) in pre-term infants, As an adjuvant to vaccines to stimulate immunity, Gastrointestinal infections & Respiratory Infections.

****L. Rhamnosus GG – Age group help in treatment of Acute infectious diarrhea, Antibiotic-associated diarrhea (AAD), Nosocomial diarrhea,

Acute Gastroenteritis (AGE), Irritable bowel syndrome (IBS), Preventing infections, Allergic diseases, C. difficile diarrhea Pouchitis, Adjuvant therapy for H. pylori Eradication.

Proved Advantages & Clinical Benefits of LGG Probiotic Strains Use:

- Lactobacillus rhamnosus GG (ATCC 53103) has a safe history of use in since 1990

Can even be given to a 24 hrs old neonate..!

- Clinically studied in various age group population starting from new born preterm infants to elderly population
- Clinically studied at various dosage range starting (120mn CFU to 2000bn CFU/d)

Do probiotics work in Acute Infectious Diarrhea?

Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations

Roberto Berni Canani, assistant professor of paediatrics,¹ Pia Cirillo, paediatrician,¹ Gianluca

63 trial, 8014 subjects

That study concluded that:

- Its use reduced the duration of diarrhea by around 25 hours,
- Risk of diarrhea be > 4 days by 59%,
- & one fewer diarrheal stool on day 2 after the intervention.

Comparative clinical study; L. rhamnosus GG vs. B. clausii vs. S. boulardii :

- Study design:

This Study designed to compare the efficacy of 5 different preparations recommended to parents in the treatment of acute diarrhea in children.

- Design: Prospective randomized controlled clinical trial.
- Study Arm: N=571 children (age 3-36 months).
- Duration: 5 days.

That study concluded that ... The use of LrGG P. Strains;

- Reduce in duration of diarrhea:

LrGG group has shown highest & significant efficacy in terms of reducing duration of diarrhea compared to other probiotics & ORS group.

- Reduce in daily stool outputs:

LrGG group has shown significant reduction in terms of no. of stools per day on Day-2 compared to other probiotics & ORS group.

- Improve in stool consistency:

LrGG group has shown significant improvement in terms of stool consistency on

Day-2 compared to other probiotics & ORS group.

Group	Treatment	Dosage (twice daily)
1	Control: Oral rehydration solution (ORS) (N=92)	-
2	Saccharomyces boulardii (N=91)	5 billion CFU/dose
3	Bacillus clausii (N=100)	1 billion CFU/dose
4	Enterococcus faecium (N=91)	0.075 CFU/dose
5	Lactobacillus rhamnosus GG (ATCC 53103) (N=100) (uncoated)	6 billion CFU/dose

Recent Content Analysis Report of Various Probiotic Brands (Indian Pediatrics, April 2018 Issue ...)

Comparative Study of 3 Brands ... Enterogermina vs. Tufpro vs. Darolac Aqua;

These figure that show us the study;

RESEARCH LETTER

TABLE I CONTENT ANALYSIS OF THREE COMMERCIALY AVAILABLE PROBIOTIC PREPARATIONS CONTAINING *BACILLUS CLAUSII*

Parameter	Product 1	Product 2	Product 3
Species on label	<i>Bacillus clausii</i>	<i>Bacillus clausii</i>	<i>Bacillus clausii</i>
Isolated species	<i>Bacillus clausii</i>	<i>Bacillus subtilis</i>	<i>Bacillus subtilis</i>
Label count	2 × 10 ⁹	2 × 10 ⁹	2 × 10 ⁹
Isolated species count			
Batch 1	1 × 10 ⁹	4 × 10 ⁸	5 × 10 ⁹
Batch 2	2.5 × 10 ⁸	2.5 × 10 ⁶	2 × 10 ⁸
Batch 3	1 × 10 ⁹	1.6 × 10 ⁸	7 × 10 ⁸
Batch 4	2 × 10 ⁹	3.4 × 10 ⁸	1.3 × 10 ⁸

Product 2 (Tufpro – Expiry range: 01/18 – 08/18) and Product 3 (Darolac Aqua – Expiry range: 12/17 – 09/18). The expiry date of products as mentioned by manufacturer was two years for all three products. MALDI-TOF-MS identification method (Matrix Assisted Laser Desorption Ionization Method Time of Flight– Mass Spectrometry) was used to identify bacterial species. Plate count method was used and colonies were counted as Colony Forming Units (CFU)/sample using Miles and Mishra method [2,3].

Only Product 1 was found to contain a homogenous population of *Bacillus clausii*, whereas Product 2 and Product 3 showed growth of *Bacillus subtilis* species in the samples. None of the samples had uniform viable bacterial counts across all samples as mentioned on the labels (Table I).

Funding: None. Competing interest: None stated.

PANKAJ YADAV¹, PANKAJ SHARMA² AND ROHIT ARORA¹
 Departments of ¹Neonatology and ²Microbiology, Apollo Cradle, Gurgaon, Haryana, India. drpankajyadav05@gmail.com

REFERENCES

- Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics Consensus Statement on the Scope and Appropriate Use of the Term Probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506-14.
- Miles AA, Mishra SS, Irvin JO. The estimation of bactericidal power of the blood. J Hyg (Lond). 1938;38:732-49.
- Hedges AJ. Estimating the precision of serial dilutions and viable bacterial counts. Int J Food Microbiol. 2002;76:207-14.

That comparative review stated only product 1 was found to contain a homogenous population of bacillus clausii whereas product 2 and product 3 showed growth of bacillus subtilis species in the samples.

Conclusions

Our mini review aims to use of the specific probiotic strains, namely Lactobacillus rhamnosus GG (LGG) and Saccharomyces boulardii, for the management of children with acute gastroenteritis (AGE) as an adjunct to rehydration therapy.²

The aim of this Mini Review also is to show us the role of probiotic in the treatment of acute diarrhea in children, we review the evidence of several

Probiotics modalities for AD treatment. We describe the Clinical Impact & prevalence of Acute Diarrhea in children and its complications, provide an overview of current treatments, and finally, discuss recent emergent Gut approaches to AD management. Specifically, we will describe - in a Comparative study - on the utility of different kinds of Probiotics known & used and common natural products in the treatment of acute cases of AD and focus on recent, high-quality studies. Adverse effects and potential interactions of each therapy will be highlighted where

applicable.

Some probiotics agents have a Benifitairy effects on the onset, course of acute Diarrheal illnesses but still in need for further reviews on the side effects & safety of such agents.

References

1. Acute Diarrhea in Children. Radlović N, Leković Z, Vuletić B, Radlović V, Simić D. *Srp Arh Celok Lek.* 2015 Nov-Dec; 143(11-12):755-62.
2. The global problem of childhood diarrhoeal diseases: emerging strategies in prevention and management. Mokomane M, Kasvosve I, de Melo E, Pernica JM, Goldfarb DM. *Ther Adv Infect Dis.* 2018 Jan;5(1):29-43.
3. Management of acute gastroenteritis in children. Wielgos K, Setkowicz W, Pasternak G, Lewandowicz-Uszyńska A. *Pol Merkur Lekarski.* 2019 Aug 30;47(278):76-79.
4. Interventions to reduce post-acute consequences of diarrheal disease in children: a systematic review. Pavlinac PB, Brander RL, Atlas HE, John-Stewart GC, Denno DM, Walson JL. *BMC Public Health.* 2018 Feb 1;18(1):208.
5. Comparative effectiveness and safety of interventions for acute diarrhea and gastroenteritis in children: A systematic review and network meta-analysis. Florez ID, Veroniki AA, Al Khalifah R, Yepes-Nuñez JJ, Sierra JM, Vermooij RWM, Acosta-Reyes J, Granados CM, Pérez-Gaxiola G, Cuello-García C, Zea AM, Zhang Y, Foroutan N, Guyatt GH, Thabane L. *PLoS One.* 2018 Dec 5;13(12):e0207701.
6. Probiotic Bacterial and Fungal Strains: Claims with Evidence. Szajewska H, Konarska Z, Kołodziej M. *Dig Dis.* 2016;34(3):251-9
7. Probiotic mechanisms of action. Halloran K, Underwood MA. *Early Hum Dev.* 2019 Aug;135:58-65.
8. Clinical Uses of Probiotics. Islam SU. *Medicine (Baltimore).* 2016 Feb;95(5):e2658.
9. Probiotics in Children: What Is the Evidence? Hojsak I. *Pediatr Gastroenterol Hepatol Nutr.* 2017 Sep;20(3):139-146.
10. Probiotics and prebiotics in infectious gastroenteritis. Vandenplas Y. *Best Pract Res Clin Gastroenterol.* 2016 Feb;30(1):49-53
11. Probiotics for Prevention and Treatment of Diarrhea. Guarino A, Guandalini S, Lo Vecchio A. *J Clin Gastroenterol.* 2015 Nov-Dec;49 Suppl 1:S37-45.
12. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. Barnes D, Yeh AM. *Nutr Clin Pract.* 2015 Dec;30(6):747-59.
13. Probiotics for Gastrointestinal Conditions: A Summary of the Evidence. Wilkins T, Sequoia J. *Am Fam Physician.* 2017 Aug 1;96(3):170-178.
14. Probiotics in digestive diseases: focus on Lactobacillus GG. Pace F, Pace M, Quartarone G. *Minerva Gastroenterol Dietol.* 2015 Dec;61(4):273-92.
15. Prophylactic use of probiotics for gastrointestinal disorders in children. Perceval C, Szajewska H, Indrio F, Weizman Z, Vandenplas Y. *Lancet Child Adolesc Health.* 2019 Sep;3(9):655-662.
16. Role of prebiotics and probiotics in the functionality of the microbiota in the patients receiving enteral nutrition]. Ballesteros Pomar MD, González Arnaiz E. *Nutr Hosp.* 2018 Apr 3;35(Spec no2):18-26.
17. Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children - a 2019 update. Szajewska H, Kołodziej M, Gieruszczak-Białek D, Skórka A, Ruszczyński M, Shamir R. *Aliment Pharmacol Ther.* 2019 Jun;49(11):1376-1384.
18. Efficacy of Lactobacillus rhamnosus GG in treatment of acute pediatric diarrhea: A systematic review with meta-analysis. Li YT, Xu H, Ye JZ, Wu WR, Shi D, Fang DQ, Liu Y, Li LJ. *World J Gastroenterol.* 2019 Sep 7;25(33):4999-5016
19. Probiotics for treating acute infectious diarrhea, Cochrane Database of systematic Reviews, 2010 ... Stephen J Allen, Elizabeth G Martinez, Germana V Gregorio, Leonila F Dans, (November 2010).
20. Probiotics for treatment of Acute Diarrhea in Children: Randomized clinical trial of five different preparations. Roberto Pemi Canani, Pia Cerillo, Gianluca. *BMJ* 2018
21. RECENT CONTENT ANALYSIS REPORT OF VARIOUS PROBIOTIC BRANDS: (Comparative Study of 3 Brands ... Enterogermina vs. Tufpro vs. Darolac Aqua). Pankaj Yadav, Pankaj Sharma & Rohit Arora, *Indian Pediatrics J.*, April 2018.

11.